Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Okabe, Hirohisa ^a,b   Delgado, Evan ^a   Lee, Jung Min ^a   Yang, Jing ^a   Kinoshita, Hiroki ^b   Hayashi, Hiromitsu ^b   Tsung, Allan ^c   Behari, Jaideep ^a   Beppu, Toru ^b,d   Baba, Hideo ^b   Monga, Satdarshan P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CHEMOTAXIN 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LECT2 PROTEIN, HUMAN; LECT2 PROTEIN, MOUSE; SIGNAL PEPTIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIN2 GENE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CTNNB1 GENE; DIAGNOSTIC TEST ACCURACY STUDY; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSFECTION; GLUL GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT GENE; LECT2 GENE; LEUKOCYTE; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REGUCALCIN GENE; SENSITIVITY AND SPECIFICITY; ANIMAL; GENETICS; KNOCKOUT MOUSE; LIVER TUMOR; METABOLISM;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; TUMOR MARKERS, BIOLOGICAL;

EID: 84902504187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098817     Document Type: Article

References (29)

1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
2. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, et al. (2002) Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21: 4863-4871.
3. Nejak-Bowen KN, Zeng G, Tan X, Cieply B, Monga SP (2009) Beta-catenin regulates vitamin C biosynthesis and cell survival in murine liver. J Biol Chem 284: 28115-28127.
4. Monga SP (2011) Role of Wnt/beta-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol 43: 1021-1029.
5. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, et al. (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172-1183.
6. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, et al. (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21: 8293-8301.
7. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52.
8. Han ZG (2012) Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet 13: 171-205.
9. Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, et al. (1996) Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett 52: 9-13.
10. Yamagoe S, Akasaka T, Uchida T, Hachiya T, Okabe T, et al. (1997) Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun 237: 116-120.
11. Ovejero C, Cavard C, Perianin A, Hakvoort T, Vermeulen J, et al. (2004) Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 40: 167-176.
12. Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, et al. (2012) Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 122: 586-599.
13. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP (2006) Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131: 1561-1572.
14. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M (2001) Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 20: 7812-7816.
15. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, et al. (2002) Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 62: 5685-5688.
16. Wickline ED, Du Y, Stolz DB, Kahn M, Monga SP (2013) gamma-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after beta-catenin knockdown. Neoplasia 15: 421-434.
17. Lee JM, Yang J, Newell P, Singh S, Parwani A, et al. (2013) beta-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett.
18. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, et al. (2006) Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8: 279-289.
19. Awuah PK, Rhieu BH, Singh S, Misse A, Monga SP (2012) beta-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One 7: e39771.
20. Okabe H, Beppu T, Ueda M, Hayashi H, Ishiko T, et al. (2012) Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. Int J Cancer 131: 2234-2241.
21. Dahmani R, Just PA, Perret C (2011) The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 35: 709-713.
22. Nejak-Bowen KN, Monga SP (2011) Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21: 44-58.
23. Rignall B, Braeuning A, Buchmann A, Schwarz M (2011) Tumor formation in liver of conditional beta-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32: 52-57.
24. Zhang XF, Tan X, Zeng G, Misse A, Singh S, et al. (2010) Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology 52: 954-965.
25. Sato Y, Watanabe H, Kameyama H, Kobayashi T, Yamamoto S, et al. (2004) Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc 36: 2359-2361.
26. Sato Y, Watanabe H, Kameyama H, Kobayashi T, Yamamoto S, et al. (2004) Changes in serum LECT 2 levels during the early period of liver regeneration after adult living related donor liver transplantation. Transplant Proc 36: 2357-2358.
27. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392.
28. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, et al. (2012) Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18: 4997-5007.
29. Okumura A, Unoki-Kubota H, Matsushita Y, Shiga T, Moriyoshi Y, et al. (2013) Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver. Biosci Trends 7: 276-283.